Scientific Posters, Presentations and Publications

2024 Nature Publication

• Article: “The regulatory T cell-selective interleukin-2 receptor against rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials“, Silverberg, et al.

2024 European Academy of Dermatology and Venereology (EADV) Congress

• ePoster P0662: “Serum proteomic biomarker analysis of the interleukin-2 receptor pathway agonist rezpegaldesleukin in patients with atopic dermatitis“, Yu, D.
• ePoster P0600 (Trial in Progress): “A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, International, Multicenter, Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis“, Gkalpakiotis, S.
• ePoster P2080 (Trial in Progress): “A Phase 2b Study Evaluating the Efficacy and Safety of Single Agent Rezpegaldesleukin, an Interleukin-2 Receptor (IL-2R) Pathway Agonist, in the Treatment of Severe to Very Severe Alopecia Areata“, Reich, A.

Revolutionizing Atopic Dermatitis (RAD) Conference 2024

• TiP Abstract 117-1000729: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, International, Multicenter, Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

Revolutionizing Alopecia Areata (RAA) Conference 2024

• TiP Abstract 116-1000724: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata

13th World Congress for Hair Research

• Abstract P007: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata (Rezolve AA)

2023 EADV Congress

• Abstract 6685: Efficacy and Safety of Single Agent Rezpegaldesleukin, a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study
• Abstract P0559: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

2021 Journal of Translational Autoimmunity

• Publication: NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

2020 ACR Convergence 2020 Meeting

• Presentation: NKTR-358: Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate

2020 European E-Congress of Rheumatology (EULAR)

• Presentation: NKTR-358: A PEG-conjugated rhIL-2 that selectively induces Tregs and their suppressive activity

The Promise of Interleukin-2 Therapy Meeting, Paris, France

• Presentation: Selective Expansion of Regulatory T-Cells by a Novel IL-2 Conjugate, NKTR-358, Being Developed for the Treatment of Autoimmune Diseases, Christie Fanton, PhD

2019 EULAR European Congress of Rheumatology

2019 American College of Rheumatology Annual Meeting

• Abstract 98: “Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases”, Fanton, C., et al.

2019 EULAR European Congress of Rheumatology

• Oral Presentation: Selective Expansion of Regulatory T-Cells in Humans by a Novel IL-2 Conjugate T-reg Stimulator, NKTR-358, Being Developed for the Treatment of Autoimmune Diseases, Brian Kotzin, M.D.

Treg Directed Therapy for Autoimmune Disorders Meeting – May 2018

• Presentation: NKTR-358: An IL-2 Pathway Agonist that Selectively Expands and Activates Regulatory T cells for the Treatment of Allergy and Autoimmune Disease

Antigen-Specific Immune Tolerance Drug Development Summit – April 2018

• Presentation: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases

American College of Rheumatology Annual Meeting, San Diego, CA

• Poster Abstract 2715: NKTR-358: A Selective, First-in-Class IL-2 Pathway Agonist Which Increases Number and Suppressive Function of Regulatory T Cells for the Treatment of Immune Inflammatory Disorders, Langowski, J., et al.

13th Annual World Congress on Inflammation

• Presentation: NKTR-358: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders

European Congress of Rheumatology (EULAR) 2024

• POS0465: A novel therapeutically active anti-TNFR2 agonistic antibody promotes Treg proliferation and induction of Treg functional markers

2024 ACR Convergence

• Abstract 1866120: “A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways”, Kivimae, S.

2025 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

• Presentation: NKTR-255 vs Placebo to Enhance Complete Responses and Durability Following CD19-directed CAR-T Therapy in Patients with Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL)

66th American Society of Hematology (ASH) Annual Meeting

• Poster 2068: NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)

2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Late-breaking Abstract (LBA) 1489: REStoring lymphoCytes Using NKTR-255 after chemoradiothErapy in solid tumors (RESCUE): Preplanned Interim Safety and Efficacy Analysis

65th American Society of Hematology (ASH) Annual Meeting

• Poster 2063: Optimizing Ex-vivo Expanded NK Cell- Mediated Cellular Cytotoxicity by Obinutuzumab Combined With NKTR-255 in Burkitt Lymphoma (BL)

64th American Society of Hematology (ASH) Annual Meeting & Exposition

• Poster 4652: Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
• Poster 3335: A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multi-center Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR®

• Presentation (Abstract 27): “Targeting Ewing sarcoma, Osteosarcoma and Neuroblastoma with Anti-MCAM Chimeric Antigen Receptor Modified Natural Killer Cells” Luo, W., et al.
  • Poster Presentation
• Poster (Abstract 201): “Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell- Mediated Cytotoxicity Combined with anti-CD20 or anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)” Chu, Y., et al.

63rd American Society of Hematology (ASH) Annual Meeting & Exposition

• Poster 3134: Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
• Poster 2815: Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-cells: Preliminary Results from a Phase 1 Study

2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Poster 957: NKTR-255 + Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose-escalation Study

2021 European Society for Medical Oncology (ESMO) Congress

• TiP Poster 1026TiP: Phase 1b/2, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors

2021 Future Oncology

• Publication: Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

2021 Journal for ImmunoTherapy of Cancer

• Publication: NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

62nd American Society of Hematology (ASH) Annual Meeting & Exposition

• Abstract 667: Restoring NK Cell Activities in Multiple Myeloma with IL-15 Receptor Agonist NKTR-255, Fernández, F., et al.
• Abstract 825: Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL), Chu, Y., et al.

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract 355: First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies, Shah, N., et al.

61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL

• Abstract 2866: Combination of NKTR-255, a polymer conjugated human IL-15, with CD19 CAR T cell immunotherapy in a preclinical lymphoma model, Chou, C., et al.
• Abstract 4398: Restoring innate and adaptive immune repertoire in multiple myeloma for therapeutic application, Fernandez, R., et al.
• TiP Abstract 4459: A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma, Shah, N., et al.

2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract P619: NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models, Kivimäe, S., et al.
• Abstract P622: Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist, Miyazaki, T., et al.

4th Congress of European Hematology Association (EHA)

• Abstract # PS1208: Effects Of NKTR-255, A Polymer Conjugated Human IL-15, on Efficacy of CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model, Chou, C., et al.

AACR 2019

• Abstract 3265/Poster Board 15: NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma model, Miyazaki, T., et al.

2018 ASH 60th Annual Meeting

• Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey, Miyazaki, T., et al.

SITC 2018

• Abstract #418: Pre-clinical investigation of NKTR-255, a polymer-conjugated IL-15 with a potent NK cell dependent anti-tumor efficacy, Miyazaki, T., et al.
• Abstract #422: A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells, Robinson T., et al.

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

• Poster T-039: NKTR-255 Exhibits Target Mediated Drug Disposition and Stimulates Proliferation of Cytotoxic Immune Cells in Cynomolgus Monkeys

CHI 3rd Annual NK Cell-Based Cancer Immunotherapy Conference, Boston, MA

• NKTR-255: Accessing the Immunotherapeutic Potential of IL-15 for NK Cell Therapies

CHI 2nd Annual Emerging Immuno-Oncology Targets Conference, Boston, MA

• NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

• Poster #P332: Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology, Kirk, P., et al.

2017 American Association for Cancer Research (AACR) Annual Meeting

• Abstract 1603/Poster 11: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation

2016 SITC Annual Meeting

• Poster: NKTR-255: an IL-15-based therapeutic with optimized biological activity and anti-tumor efficacy